Keyword: Pacific Research Institute
Growing the biosimilar market could lead to significant healthcare cost savings, according to a new report.
Wait times are long in Canada under a single-payer system, raising debate about whether they would translate to the U.S. under Medicare-for-all.
Despite railing against the role of middlemen—namely PBMs—in rising drug prices, HHS appears poised to introduce some into Part B.
These days, when the federal government turns in one direction, California veers in the other—and in the case of health care, it’s a sharp swerve.
As lawmakers in Washington debate the next steps for U.S. healthcare reform, California officials may be looking to San Francisco as a model for the state.
While some say MACRA enjoys bipartisan support and is here to stay, two authors hope the Trump administration will introduce changes.